COMMUNICATIONS
imine 3d :5.00 g, 12.9 mmol) in CH2Cl2 :10 mL) was added by syringe to
the catalyst solution at 08C. Stirring the mixture for 10 min gave an orange
solution to which was rapidly added ethyl diazoacetate :1.484 mL,
14.2 mmol) by syringe. Some bubbling was noted after the addition. The
reaction was allowed to proceed for 6 hat 0 8C and then for 14 h at room
temperature :228C). The reaction mixture was transferred to a 500-mL
flask, diluted with hexanes :250 mL), and then the volatiles were removed
under vacuum to give the crude aziridine 3d as an off-white solid. The
1H NMR spectrum of this material revealed 3d with cis:trans ꢀ 50:1 and
indicated that <1% of 4d and 5d were formed. Purification of 3d by
column chromatography on silica gel with a mixture of ethyl acetate:hex-
anes :3:7) gave aziridine 3d :5.20 g, 11 mmol) as a white solid in 85% yield.
The optical purity of this material was determined to be 96% ee by HPLC
analysis :OD-H column). Crystallization from hexanes:CH2Cl2 :10:1,
300 mL) gave 3d :4.43 g) with99% ee. A second crop was taken but
found to be only 90% ee. Spectral data for 3d: m.p. 141 ± 1438C :hex-
anes:CH2Cl2); 1H NMR :400 MHz, CDCl3): d 0.99 :t, J 7 Hz, 3H), 2.24
:s, 3H), 2.25 :s, 3H), 2.68 :d, J 7 Hz, 1H), 3.18 :d, J 7 Hz, 1H), 3.95 :s,
1H), 3.95 :m, 2H), 7.07 :d, J 9 Hz, 1H), 7.19 :m, 1H), 7.28 :m, 7H), 7.45
:d, J 7 Hz, 2H), 7.81 :d, J 7 Hz, 2H). 13C NMR :100.6 MHz, CDCl3):
d 13.84, 20.64, 46.57, 47.03, 60.89, 77.49, 122.75, 122.78, 126.05, 127.18,
127.30, 127.45, 127.61, 128.55, 128.65, 133.97, 141.35, 141.57, 142.21, 167.45
168.07, 168.24; IR :thin film) 3030 :w), 2980 :w), 1770 :s), 1731 :s),
1600 cmÀ1 :m); MS :EI): m/z :relative intensity): 474 :21) [M1], 306 :12),
195 :10), 167 :100); m/z calcd for C28H27NO6: 474.1903, found 474.1903.
Elemental analysis calcd for C28H27NO6: C 71.02, H 5.75, N 2.96; found: C
71.23, H 5.88, N 2.94. [a]2D3 À17.38, :C 1 from CH2Cl2) taken on 99% ee
material :HPLC). Further experimental details can be found in the
Supporting Information.
[3] J. C. Antilla, W. D. Wulff, J. Am. Chem. Soc. 1999, 121, 5099.
[4] For other applications of the VAPOL ligand, see a) J. Bao, W. D. Wulff,
A. L. Rheingold, J. Am. Chem. Soc. 1993, 115, 3814; b) J. Bao, W. D.
Wulff, Tetrahedron Lett. 1995, 36, 3321; c) J. Bao, W. D. Wulff, J. B.
Dominy, M. J. Fumo, E. B. Grant, A. C. Rob, M. C. Whitcomb, S.-M.
Yeung, R. L. Ostrander, A. L. Rheingold, J. Am. Chem. Soc. 1996, 118,
3392; d) D. P. Heller, D. R. Goldberg, W. D. Wulff, J. Am. Chem. Soc.
1997, 119, 10551.
[5] The VANOL ligand was prepared according to the same procedure that
has been reported for the VAPOL ligand.[4c]
[6] A second crop was taken but had only approximately 90% ee.
[7] The optical rotation of an authentic sample of l-DOPAwas found to be
[a]D À8.28.
Stereoselective Synthesis of RP- and
SP-Dithymidine Phosphorothioates via Chiral
Indolooxazaphosphorine Intermediates
Derived from Tryptophan**
Yixin Lu and George Just*
The use of phosphorothioates as DNA analogues useful in
antisense-based therapy is well established[1] and led to the
development of Vitravene as the first antisense drug.[2]
Several other phosphorothioate oligonucleotides :PS-Oligos)
are in clinical trials. Although Stec et al. described an elegant
oxathiaphospholane-based approach[3]for preparing diaster-
eomerically pure phosphorothioates, it has not been used for
large-scale production of PS-Oligos, which are still used as a
mixture of about 106 diastereomers. The use of cyclic N-
acylphosphoramidites as promising monomers for the stereo-
controlled synthesis of phosphorothioates was recently re-
ported by Beaucage et al.[4]
Previously, we developed cyclic phosphoramidites[5]suchas
sugar-derived oxazaphosphorinanes,[5b,c] indolooxazaphos-
phorines :a),[5e, f] and indoleimidazoles[5i] for the stereoselec-
tive synthesis of PS-Oligos. Here we report on the use of
promising indolooxazaphosphorine precursors derived from
tryptophan which do not require a difficult chromatographic
separation and may form the basis of a practical process.
As demonstrated in the indolooxazaphosphorine ap-
proach,[5f] chiral auxiliary a led to the stereoselective synthesis
of phosphorothioate in solution. When it was applied to solid-
phase synthesis, a b-elimination caused rearrangement to give
Received: August 9, 2000 [Z15611]
[1] a) D. Tanner, Angew. Chem. 1994, 106, 625; Angew. Chem. Int. Ed.
Engl. 1994, 33, 599; b) W. H. Pearson, B. W. Lian, S. C. Bergmeier in
Comprehensive Heterocyclic Chemistry II, Vol. 1A :Ed.: A. Padwa),
Pergamon, Oxford, 1996, p. 1; c) K. M. L. Rai, A. Hassner in Compre-
hensive Heterocyclic Chemistry II, Vol. 1A :Ed.: A. Padwa), Pergamon,
Oxford, 1996, p. 61; d) J. Sweeney, H. M. I. Osborn, Tetrahedron:
Asymmetry 1997, 8, 1693; e) R. S. Atkinson, Tetrahedron 1999, 55, 1519.
[2] For previous work on catalytic asymmetric aziridinations, see a) D. A.
Evans, K. A. Woerpel, M. M. Hinman, M. M. Faul, J. Am. Chem. Soc.
1991, 113, 726; b) R. E. Lowenthal, S. Masamune, Tetrahedron Lett.
1991, 32, 7373; c) Z. Li, K. R. Conser, E. N. Jacobsen, J. Am. Chem. Soc.
1993, 115, 5326; d) D. A. Evans, M. M. Faul, M. T. Bilodeau, B. A.
Anderson, D. M. Barnes, J. Am. Chem. Soc. 1993, 115, 5328; e) K.
Noda, N. Hosoya, R. Irie, Y. Ito, T. Katsuki, Synlett 1993, 469; f) D. A.
Evans, M. M. Faul, M. T. Bilodeau, J. Am. Chem. Soc. 1994, 116, 2742;
g) D. Tanner, P. G. Andersson, A. Harden, P. Somfai, Tetrahedron Lett.
1994, 35, 4631; h) Z. Li, R. W. Quan, E. N. Jacobsen, J. Am. Chem. Soc.
1995, 117, 5889; i) H. Nishikori, T. Katsuki, Tetrahedron Lett. 1996, 37,
9245; j) A. M. Harm, J. G. Knight, G. Stemp, Synlett 1996, 677; k) P.
Muller, C. Baud, Y. Jacquier, M. Moran, I. Nageri, J. Phys. Org. Chem.
1996, 9, 341; l) T.-S. Lai, H.-L. Kwong, C.-M. Che, S.-M. Peng, Chem.
Commun. 1997, 2373; m) M. J. Sodergren, D. A. Alonso, P. G. Ander-
sson, Tetrahedron: Asymmetry 1997, 8, 3563; n) K. B. Hansen, N. S.
Finney, E. N. Jacobsen, Angew. Chem. 1995, 107, 750; Angew. Chem.
Int. Ed. Engl. 1995, 34, 676; o) K. G. Rasmussen, K. A. Jorgensen, J.
Chem. Soc. Chem. Commun. 1995, 1401; p) V. K. Aggarwal, A.
Thompson, R. V. H. Jones, M. C. H. Standen, J. Org. Chem. 1996, 61,
8368; q) L. Casarrubios, J. A. Perez, M. Brookhart, J. L. Templeton, J.
Org. Chem. 1996, 61, 8358; r) H.-J. Ha, K.-H. Kang, J.-M. Suh, Y.-G.
Ahn, Tetrahedron Lett. 1996, 37, 7069; s) K. G. Rasmussen, K. A.
Jorgensen, J. Chem. Soc. Perkin Trans. 1 1997, 1287; t) C. Langham, P.
Piaggio, D. Bethell, D. F. Lee, P. McMorn, P. C. Bulman Page, D. J.
Willock, C. Sly, F. E. Hancock, F. King, G. J. Hutchings, J. Chem. Soc.
Chem. Commun. 1998, 1601; u) S. Minakata, T. Andl, M. Nishimura, I.
Ryu, M. Komatsu, Angew. Chem. 1998, 110, 3596; Angew. Chem. Int.
Ed. 1998, 37, 3392; v) P. Müller, C. Baud, Y. Jacquier, Can. J. Chem.
1998, 76, 738; w) S. K. Bertilsson, L. Tedenborg, D. A. Alonso, P. G.
Andersson, Organometallics 1999, 18, 1281; x) K. Juhl, R. G. Hazell,
K. A. Jorgensen, J. Chem. Soc. Perkin Trans. 1 1999, 2293.
[*] Prof. Dr. G. Just, Dr. Y. Lu
Department of Chemistry
McGill University
Montreal, PQ, H3A 2K6 :Canada)
Fax : :1)514-398-3797
[**] This work was financially supported by Natural Science and Engineer-
ing ResearchCouncil of Canada :NSERC). We thank Nadim Saadeh
and Dr. Orval Mamer, McGill University biomedical mass spectro-
scopy unit, for recording mass spectra.
Supporting information for this article is available on the WWW under
Angew. Chem. Int. Ed. 2000, 39, No. 24
ꢀ WILEY-VCH Verlag GmbH, D-69451 Weinheim, 2000
1433-7851/00/3924-4521 $ 17.50+.50/0
4521